Skip to main content

iwCLL 2023 Main banner

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

T
1202
T cell type abundance and gene expression patterns in the context of clinical progression of treatment-naïve CLL/MBL patients from the OxPLoreD study
Pathogenesis of CLL

Favorite
1044
T cells from chronic lymphocytic leukemia patients are not exhausted but show signs of senescence, providing alternative clues for improvement
Pathogenesis of CLL

Favorite
1212
Targeted agents in chronic lymphocytic leukemia (CLL): Data on outcomes and subsequent therapies of patients observed within the German CLL Study Group (GCLLSG) registry
Therapy of CLL

Favorite
1023
Targeting NF-κB-inducing kinase (NIK) in chronic lymphocytic leukaemia
Therapy of CLL

Favorite
1026
Targeting the pro-inflammatory protein S100-A9 in Chronic Lymphocytic Leukemia
Pathogenesis of CLL

Favorite
1058
T-cell Transcriptional and Mitochondrial Fitness Reprogramming in CLL Using PI3Kδ Inhibitors
Pathogenesis of CLL

Favorite
1143
The Economic Benefits of Time Off Treatment: Real-World HRU, Costs, and Subsequent Treatment with Fixed Duration Venetoclax among Patients with Chronic Lymphocytic Leukemia
Past, Present, and Future in CLL

Favorite
1219
The evolution of treatments and outcome of patients with chronic lymphocytic leukemia treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: a monocentric experience of the Last 30 Years.
Past, Present, and Future in CLL

Favorite
1208
The HEALTH4CLL study: optimization of behavioral interventions for patients with chronic lymphocytic leukemia
Clinical Challenges in CLL

Favorite
1151
The Impact of BTK Inhibitors on COVID-19 Outcomes in Patients with Chronic Lymphocytic Leukemia: A real-world study in the Omicron wave
Therapy of CLL

Favorite
1010
The interplay between BcR signaling and the p53 pathway upon DNA damage in primary CLL cells
Pathogenesis of CLL

Favorite
1020
The mechanical properties of CLL cells are linked to the actin cytoskeleton and are target of BTK inhibitors
Therapy of CLL

Favorite
1004
The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia
Clinical Challenges in CLL

Favorite
1039
The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Pathogenesis of CLL

Favorite
1054
The RNA-binding protein Musashi2 is regulated by NOTCH1/KLF4 pathway and support tumor survival keeping CLL cells in proliferative niches during disease progression
Pathogenesis of CLL

Favorite
1145
The role of 18F-FDG PET-CT in Richter Transformation and accelerated CLL
Clinical Challenges in CLL

Favorite
1013
The role of artificial intelligence in differential diagnosis and prognostic significance of Small B-cell lymphoma
Clinical Challenges in CLL

Favorite
1148
Time to treatment initiation in 17p-deleted Chronic Lymphocytic Leukemia has no influence on overall survival
Therapy of CLL

Favorite
1162
Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon
Therapy of CLL

Favorite
1005
Toll-like receptor 9 signalling in CLL: a resistance mechanism to B-cell receptor-targeted treatments, and a potential tool for therapeutic stratification.
Therapy of CLL

Favorite
4004
Tracking CLL cells with mutation in the TP53 gene using scRNAseq in relapsed/refractory patients
Pathogenesis of CLL

Favorite
1006
Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL
Clinical Challenges in CLL

Favorite
1021
Transcriptional correlation analysis of the CD180/MD-1 complex and toll-like receptors and signaling lymphocyte activation family receptors in chronic lymphocytic leukemia.
Pathogenesis of CLL

Favorite
1142
Treatment of symptomatic paraneoplastic fluidothorax in CLL with novel agents: a single-center case series.
Therapy of CLL

Favorite
1122
Treatment Patterns and Outcomes of Patients with TP53-Mutated Chronic Lymphocytic Leukemia
Clinical Challenges in CLL

Favorite
1119
Treatment Strategies and Outcomes for Double Refractory chronic lymphocytic leukemia; A single center experience
Clinical Challenges in CLL

Favorite